SITC 29th Annual Meeting: Concurrent Session - Coinhibition and Costimulation: Targets and Strategies November 7-9, 2014Gaylord National Hotel & Convention Center National Harbor, MDSITC 29th Annual Meeting Organizers Arthur A. Hurwitz, PhD - National Cancer Institute Kim A. Margolin, MD - Stanford University Daniel E. Speiser, MD - Ludwig Center for Cancer Research of the University of Lausanne Walter J. Urba, MD, PhD - Earle A. Chiles Research Institute, Providence Cancer CenterProgram SummaryFrom the Society for Immunotherapy of Cancer (SITC), these enduring materials from the SITC 29th Annual Meeting addresses the great impact on the development of effective cancer immunotherapy that the identification of molecules involved in the regulation of T-cell response to antigen has had. Blockade of the inhibitory molecules CTLA-4, PD-1, PDL-1 has led to significant clinical benefits in patients with melanoma and the first trial of combined CTLA-4 and PD-1 blockade indicates possible superior results. Other inhibitory molecules (LAG-3) and costimulatory molecules (OX40 and CD40) have been targeted in early clinical trials. It is important to understand the effects of targeting these receptors singly and in combination to ensure future development of effective immunotherapy. About the SITC 29th Annual MeetingThe SITC 29th Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consisted of cutting-edge research presentations by experts in the field, oral and poster abstract presentations, and ample opportunities for structured and informal discussions, including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as important society projects. #GastrointestinalCancers #Melanoma #PresentationSlides #Video #AnnualMeeting #SITC #AdoptiveCellTherapy #CombinationTherapy #TherapeuticAntibodies #AdverseEvents #Toxicities #Clinician #Industry #Oncologist #Researcher #2014
Meeting: SITC 29th Annual Meeting; Session: Concurrent Session — Coinhibition and Costimulation: Targets and Strategies; Presentation: OX40 Immunotherapy in Cancer Patients: Immunological Observations and Implications for T Cell Immunotherapy; Presenter: Brendan D. Curti, MD – Earle A. Chiles Research Institute, Providence Cancer Center; Date: November 8, 201400:24:28
Meeting: SITC 29th Annual Meeting; Session: Concurrent Session — Coinhibition and Costimulation: Targets and Strategies; Presentation: CD40 Agonists in Cancer Immunotherapy; Presenter: Robert H. Vonderheide, MD, DPhil – University of Pennsylvania; Date: November 8, 201400:24:57